About Solume
A company built on the conviction that cures are possible.
Founded by researchers and clinicians who refused to accept the status quo, Solume is driven by a singular goal: to eliminate disease at its source.
Our Story
From academic insight to clinical impact
Solume was founded in 2018 when a team of molecular biologists and clinical researchers at the forefront of disease-mechanism science recognized a fundamental disconnect in pharmaceutical development: too many programs were designed to manage chronic conditions rather than resolve them.
Our founders established Solume with a rigorous, mechanism-first approach — mapping the causal biology of each target disease and engineering therapies that intervene at the precise molecular origin. Today, that founding philosophy drives every program in our pipeline.
Our Values
Principles that guide our science and our culture
Root-Cause Focus
Every program begins with the question: what is the fundamental mechanism driving this disease?
Patient-Centered
Our success is measured not by publications or patents, but by the patients whose lives we transform.
Scientific Rigor
We pursue only the highest-quality evidence, subjecting every hypothesis to rigorous validation.
Global Access
We are committed to ensuring that our therapies reach patients everywhere, regardless of geography.
Leadership
Led by world-class scientists and industry veterans
Dr. Elena Voss
Chief Executive Officer
Former VP of R&D at a leading oncology biotech. 20+ years in drug development.
Dr. Marcus Chen
Chief Scientific Officer
Pioneer in molecular pathway mapping. Published 80+ peer-reviewed papers.
Sarah Lindström
Chief Operating Officer
Scaled three pharmaceutical companies from preclinical to commercial stage.